Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (April 2025)
21 slides from Cns Pharmaceuticals's investor presentation, Apr 9, 2025
Slide 1: April 2025
1 NASDAQ: CNSP April 2025
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial
Slide 3: Overview
3 Overview Developing Anti - Cancer Drug Candidates for the Treatment of Primary and Metastatic Brain Cancers Strong Financial Position Proven Clinical Development "Engine" with Global Trial Site Network in Place to Accelerate Complex CNS Focused Trials Advancing Lead Product Candidate, TPI 287 for
Slide 4: A Focused and Targeted CNS Oncology Pipeline
A Focused and Targeted CNS Oncology Pipeline 4 Highlights Phase 3 Phase 2 Phase 1 Preclinical Indication Program • Studied in over 350 patients to date • Plan to engage with regulators to design potential registration study in 2025 Glioblastoma Multiforme (GBM) TPI 287 A Much Bigger Story Beyond GBM
Slide 5: Established "Engine" to Execute Global CNS Clinical Trials
Established "Engine" to Execute Global CNS Clinical Trials 5 Key Learnings and Established Network From Berubicin Monotherapy Potentially Pivotal Trial CNS Focused Clinical Trial Sites Successfully Built CNS Trial Network and Enrolled Patients in Record Time, All During a Global Pandemic Countries P
Slide 6: Proven Clinical Development Infrastructure Optimized for Brain Cancer Drug Development
Proven Clinical Development Infrastructure Optimized for Brain Cancer Drug Development 6 Relationships • Deliberate establishment of a global, CNS focused network • Commitment to work in this disease • Deep understanding of the landscape of clinical trials in GBM Program Development Infrastructure &
Slide 7: Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) 7 1: https://braintumor.org/take - action/about - gbm/ 2: 8 Major Markets includes USA, France, Germany, Italy, Spain, UK, Japan and urban China 3: Global Data, “Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027” (2017) One of the most aggressive
Slide 8: The Blood Brain Barrier (BBB)
8 The Blood Brain Barrier (BBB) Key Functions • Protection: • Blocks toxins, pathogens and potentially harmful molecules from entering the brain by transporters that bind to these substances and deliver them back to the bloodstream • Selective Permeability : • Allows essential nutrients like glucose
Slide 9: TPI 287: Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane
9 TPI 287 Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Slide 10: TPI 287: A Novel Taxane Derivative
10 TPI 287: A Novel Taxane Derivative TPI 287 Paclitaxel • Taxanes • A class of chemotherapy that binds to microtubules and prevents them from functioning normally, which stops cancer cells from dividing • A substrate for P - glycoprotein ( Pgp ), which is upregulated in cells that become taxane - r
Slide 11: Readily Penetrates the Blood Brain Barrier in Animal Models
11 Readily Penetrates the Blood Brain Barrier in Animal Models
Slide 12: Clinical Trials with TPI 287
Clinical Trials with TPI 287 12 Evaluated in multiple Phase 1 and Phase 2 studies Engaging with regulators to advance into registrational study Fast Track Designation Orphan Drug Designation with 7 years market exclusivity in the U.S. ✓ ✓ ✓ ✓
Slide 13: TPI 287 in Combination with Bevacizumab for Recurrent Glioblastoma
TPI 287 in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma 13 Progression - Free Survival Overall Survival Median OS: 13.4 mo [95% C.I. 10.9, 17.9] 12 - month OS: 64% Median PFS: 5.5 mo [95% C.I. 4.1, 8.2] 6 - month PFS: 40%
Slide 14: Improved GBM Survival in Combination with Bevacizumab
14 * Graphs represent aggregate data from multiple studies Improved GBM Survival in Combination with Bevacizumab
Slide 15: Berubicin: Evaluation of Strategic Options May Provide Potential for Upside
15 Berubicin Evaluation of Strategic Options May Provide Potential for Upside
Slide 16: Summary of Primary Analysis of Berubicin in 2nd line GBM
Summary of Primary Analysis 16 Reported Primary Analysis of Berubicin in 2 nd line GBM Berubicin 252 Subjects BERUBICIN 168 subjects LOMUSTINE 84 subjects Randomized: 2:1 7.1 mg/m2 IV infusion for 2 hours for 3 consecutive days followed by 18 days off study drug Single oral dose of 130 mg/m2 every 6
Slide 17: Berubicin Demonstrated Comparable Overall Survival Compared to Lomustine
Berubicin Demonstrated Comparable Overall Survival Compared to Standard of Care, Lomustine 17
Slide 18: Intellectual Property
18 Intellectual Property Orphan Drug Designation gives marketing exclusivity in US market for 7 - years from approval Orphan Drug Upcoming filing after final data in the E.U. for Orphan Drug Designation may provide 10 - years of protection in Europe CNS is exploring potential new patent filings cove
Slide 19: Financial Snapshot
Financial Snapshot NASDAQ: CNSP 19 Strong Financial Position with Sufficient Capital to Fund Operations Into the First Quarter of 2025 Cash As of December 31, 2024 Volume Average 3 months Market Cap As of April 1, 2025 $6.5 Million ~50K ~$4 Million The number of shares of the registrant’s common sto
Slide 20: Management Team
20 Management Team Twenty - one years experience managing the operations, strategies and finances of public and private lifescience companies. PRESIDENT & CHIEF EXECUTIVE OFFICER John M. Climaco, Esq Over 35 years of drug development experience and responsible for the development of Carboplatin, one
Slide 21: Investor & Media Relations
21 NASDAQ: CNSP Investor & Media Relations: JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@JTCIR.com
CNS Pharmaceuticals — Investor Presentation (April 2025) on 6ix